Im pleased to share that the first participants have been dosed in two new studies of PF3944, our investigational ultra-long-acting GLP-1 receptor agonist (GLP-1 RA): VESPER-6, our Phase 3 pivotal trial evaluating monthly dosing, and SOLIS-1, a Phase 2b umbrella study evaluating PF3945 alone and in combination with our investigational ultra-long-acting amylin analog, PF3945
He is responsible for developing new and managing existing relationships with strategic industry partners, leading the negotiations/contracting, performing due diligence on new investment opportunities (both clinical trials and company investments), and managing the existing investment portfolio
Let us help you achieve sustainable weight loss with professional oversight and expert care
Some researchers have experienced significant gastrointestinal side effects because they were unknowingly taking twice their target dose
Does Tirzepatide Stop Working After A Few Months